Deniz DOĞRU, Salih EMRİ, Berrin ER, Ebru ÇELEBİOĞLU, Ebru YALÇIN, Uğur ÖZÇELİK, Nural KİPER, Özlem ERDEN AKI, Ömrüm UZUN, Murat AKOVA

Factors associated with severe lung disease in an adult population with cystic fibrosis: a single-center experience

Background/Aim: The patients with cystic fibrosis (CF) are living longer compared to the past, but respiratory failure is still the mostcommon cause of mortality. The aim of this study is to investigate factors associated with severe lung disease in a cohort of adult patientswith CF.Materials and methods: Demographic data, clinical and laboratory findings of the patients aged 18 years and more were collected andthe patients were grouped according to forced expiratory volume in 1 s (FEV1) as severe group:

PDF

___

1. O’Sullivan BP, Freedman SD. Cystic fibrosis. Lancet 2009; 373(9678): 1891-1904. doi: 10.1016/S0140-6736(09)60327-5
2. Cystic Fibrosis Foundation Patient Registry. 2016 Annual Data Report. Bethesda, Maryland, USA: Cystic Fibrosis Foundation; 2017.
3. European Cystic Fibrosis Society Patient Registry. Annual Report 2016. Karup, Denmark: European Cystic Fibrosis Society; 2018.
4. Plant BJ, Goss CH, Plant WD, Bell SC. Management of comorbidities in older patients with cystic fibrosis. Lancet Respiratory Medicine 2013; 1(2): 164-174. doi: 10.1016/S2213- 2600(13)70025-0
5. Zolin A, Bossi A, Cirilli N, Kashirskaya N, Padoan R. Cystic fibrosis mortality in childhood. Data from European Cystic Fibrosis Society Patient Registry. International Journal of Environmental Research and Public Health 2018; 15(9): 2020. doi: 10.3390/ijerph15092020
6. Kolodziej M, de Veer MJ, Cholewa M, Egan GF, Thompson BR. Lung function imaging methods in Cystic Fibrosis pulmonary disease. Respiratory Research 2017; 18(1): 96. doi: 10.1186/ s12931-017-0578-x
7. Dogru D, Cakir E, Sismanlar T, Cobanoglu N, Pekcan S et al. Cystic fibrosis in Turkey: First data from the national registry. Pediatric Pulmonology 2019; 55(2): 541-548. doi: 10.1002/ ppul.24561
8. Terheggen-Lagro S, Truijens N, van Poppel N, Gulmans V, van der Laag J et al. Correlation of six different cystic fibrosis chest radiograph scoring systems with clinical parameters. Pediatric Pulmonology 2003; 35(6): 441-445. doi: 10.1002/ppul.10280
9. Lee TW, Brownlee KG, Conway SP, Denton M, Littlewood JM. Evaluation of a new definition for chronic Pseudomonas aeruginosa infection in cystic fibrosis patients. Journal of Cystic Fibrosis 2003; 2(1): 29-34. doi: 10.1016/S1569-1993(02)00141- 8
10. Orenstein DM, Boat TF, Stern RC, Tucker AS, Charnock EL et al. The effect of early diagnosis and treatment in cystic fibrosis: a seven-year study of 16 sibling pairs. American Journal of Diseases of Children 1977; 131(9): 973-975. doi: 10.1001/ archpedi.1977.02120220039005
11. Southern KW, Munck A, Pollitt R, Travert G, Zanolla L et al. A survey of newborn screening for cystic fibrosis in Europe. Journal of Cystic Fibrosis 2007; 6(1): 57-65. doi: 10.1016/j. jcf.2006.05.008
12. Taylor-Robinson D, Whitehead M, Diderichsen F, Olesen HV, Pressler T et al. Understanding the natural progression in %FEV1 decline in patients with cystic fibrosis: a longitudinal study. Thorax 2012; 67(10): 860-866. doi: 10.1136/ thoraxjnl-2011-200953
13. Vandenbranden SL, McMullen A, Schechter MS, Pasta DJ, Michaelis RL et al. Lung function decline from adolescence to young adulthood in cystic fibrosis. Pediatric Pulmonology 2012; 47(2): 135-143. doi: 10.1002/ppul.21526
14. Harness-Brumley CL, Elliott AC, Rosenbluth DB, Raghavan D, Jain R. Gender differences in outcomes of patients with cystic fibrosis. Journal of Women’s Health 2014; 23(12): 1012-1020. doi: 10.1089/jwh.2014.4985
15. Matel JL, Milla CE. Nutrition in cystic fibrosis. Seminars in Respiratory and Critical Care Medicine 2009; 30(5): 579-586. doi: 10.1055/s-0029-1238916
16. Corey M, McLaughlin FJ, Williams M, Levison H. A comparison of survival, growth, and pulmonary function in patients with cystic fibrosis in Boston and Toronto. Journal of Clinical Epidemiology 1988; 41(6): 583-591.
17. Kerem E, Viviani L, Zolin A, MacNeill S, Hatziagorou E et al. Factors associated with FEV1 decline in cystic fibrosis: analysis of the ECFS patient registry. European Respiratory Journal 2014; 43(1): 125-133. doi: 10.1183/09031936.00166412
18. Schoni MH, Casaulta-Aebischer C. Nutrition and lung function in cystic fibrosis patients: review. Clinical Nutrition 2000; 19(2): 79-85. doi: 10.1054/clnu.1999.0080
19. Woestenenk JW, Castelijns SJ, van der Ent CK, Houwen RH. Nutritional intervention in patients with Cystic Fibrosis: a systematic review. Journal of Cystic Fibrosis 2013; 12(2): 102- 115. doi: 10.1016/j.jcf.2012.11.005
20. Moran A, Dunitz J, Nathan B, Saeed A, Holme B et al. Cystic fibrosis-related diabetes: current trends in prevalence, incidence, and mortality. Diabetes Care 2009; 32(9): 1626- 1631. doi: 10.2337/dc09-0586
21. Castellani C, Duff AJA, Bell SC, Heijerman HGM, Munck A et al. ECFS best practice guidelines: the 2018 revision. Journal of Cystic Fibrosis 2018; 17(2): 153-178. doi: 10.1016/j. jcf.2018.02.006
22. Kayani K, Mohammed R, Mohiaddin H. Cystic fibrosis-related diabetes. Frontiers in Endocrinology 2018; 9: 20. doi: 10.3389/ fendo.2018.00020
23. Widger J, Ranganathan S, Robinson PJ. Progression of structural lung disease on CT scans in children with cystic fibrosis related diabetes. Journal of Cystic Fibrosis 2013; 12(3): 216-221. doi: 10.1016/j.jcf.2012.09.005
24. Wanke T, Formanek D, Auinger M, Popp W, Zwick H et al. Inspiratory muscle performance and pulmonary function changes in insulin-dependent diabetes mellitus. American Review of Respiratory Disease 1991; 143(1): 97-100. doi: 10.1164/ajrccm/143.1.97
25. Brennan AL, Gyi KM, Wood DM, Johnson J, Holliman R et al. Airway glucose concentrations and effect on growth of respiratory pathogens in cystic fibrosis. Journal of Cystic Fibrosis 2007; 6(2): 101-109. doi: 10.1016/j.jcf.2006.03.009
26. Kerem E, Viviani L, Zolin A, MacNeill S, Hatziagorou E et al. Factors associated with FEV1 decline in cystic fibrosis: analysis of the ECFS patient registry. European Respiratory Journal 2014; 43(1): 125-133. doi: 10.1183/09031936.00166412
27. Bobadilla JL, Macek M, Jr., Fine JP, Farrell PM. Cystic fibrosis: a worldwide analysis of CFTR mutations--correlation with incidence data and application to screening. Human Mutation 2002; 19(6): 575-606. doi: 10.1002/humu.10041
28. de Gracia J, Mata F, Alvarez A, Casals T, Gatner S et al. Genotype-phenotype correlation for pulmonary function in cystic fibrosis. Thorax 2005; 60(7): 558-563. doi: 10.1136/ thx.2004.031153
29. Emerson J, Rosenfeld M, McNamara S, Ramsey B, Gibson RL. Pseudomonas aeruginosa and other predictors of mortality and morbidity in young children with cystic fibrosis. Pediatric Pulmonology 2002; 34(2): 91-100. doi: 10.1002/ppul.10127
30. Courtney JM, Bradley J, McCaughan J, O’Connor TM, Shortt C et al. Predictors of mortality in adults with cystic fibrosis. Pediatric Pulmonology 2007; 42(6): 525-532. doi: 10.1002/ ppul.20619
31. Middleton PG, Chen SC, Meyer W. Fungal infections and treatment in cystic fibrosis. Current Opinion in Pulmonary Medicine 2013; 19(6): 670-675. doi: 10.1097/ MCP.0b013e328365ab74
32. VanDyke RD, McPhail GL, Huang B, Fenchel MC, Amin RS et al. Inhaled tobramycin effectively reduces FEV1 decline in cystic fibrosis. An instrumental variables analysis. Annals of the American Thoracic Society 2013; 10(3): 205-212. doi: 10.1513/AnnalsATS.201209-082OC
33. Goss CH, MacNeill SJ, Quinton HB, Marshall BC, Elbert A et al. Children and young adults with CF in the USA have better lung function compared with the UK. Thorax 2015; 70(3): 229- 236. doi: 10.1136/thoraxjnl-2014-205718
34. Taylor-Cousar JL, Munck A, McKone EF, van der Ent CK, Moeller A et al. Tezacaftor-ivacaftor in patients with cystic fibrosis homozygous for Phe508del. New England Journal of Medicine 2017; 377(21): 2013-2023. doi: 10.1056/ NEJMoa1709846
35. Wainwright CE, Elborn JS, Ramsey BW, Marigowda G, Huang X et al. Lumacaftor-ivacaftor in patients with cystic fibrosis homozygous for Phe508del CFTR. New England Journal of Medicine 2015; 373(3): 220-231. doi: 10.1056/NEJMoa1409547
36. Ramsey BW, Davies J, McElvaney NG, Tullis E, Bell SC et al. A CFTR potentiator in patients with cystic fibrosis and the G551D mutation. New England Journal of Medicine 2011; 365(18): 1663-1672. doi: 10.1056/NEJMoa1105185
37. Smyth AR, Bell SC, Bojcin S, Bryon M, Duff A et al. European Cystic Fibrosis Society standards of care: best practice guidelines. Journal of Cystic Fibrosis 2014; 13 Suppl 1: S23-42. doi: 10.1016/j.jcf.2014.03.010
38. Yankaskas JR, Marshall BC, Sufian B, Simon RH, Rodman D. Cystic fibrosis adult care: consensus conference report. Chest 2004; 125(1 Suppl): 1S-39S.
39. Goss CH, Burns JL. Exacerbations in cystic fibrosis. 1: Epidemiology and pathogenesis. Thorax 2007; 62(4): 360-367. doi: 10.1136/thx.2006.060889